Remsima (infliximab), an anti-inflammatory biologic medicine biosimilar to the anti-TNF Remicade (infliximab), has been launched in the UK with a licence for a range of conditions, including psoriasis.
Remsima has been specifically developed to be highly similar to Remicade, which binds and blocks TNF alpha, an inflammatory substance that is overproduced in some inflammatory conditions.
Remsima was authorised by the European Medicines Agency after undergoing a comparability assessment versus Remicade. This included clinical trials involving 850 patients in 20 countries, which the manufacturers claim showed no clinically meaningful differences between the two medicines.
European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Remsima (infliximab)